How to Get Oral Micronized Progesterone in Florida

The shortest accurate route

1. Choose a clinician authorized to treat a patient located in Florida.
2. Share the treatment goal, current estrogen or other hormone therapy, uterus status, bleeding history, pregnancy possibility, allergy history, liver history, clot or cardiovascular history, cancer history, and complete medication list.
3. Ask whether telehealth is sufficient for the evaluation. Florida allows telehealth evaluation, but it does not guarantee a prescription.
4. Before accepting a capsule, check the exact manufacturer, National Drug Code (NDC), and inactive ingredients if peanut or another excipient allergy is relevant.
5. Ask the pharmacy to run the exact NDC through the current benefit rather than relying on a statewide price or coverage estimate.

There is no dependable three-to-ten-day timeline. An uncomplicated visit may move quickly, while records, evaluation of abnormal bleeding, benefit verification, or pharmacy stock can take longer.

What the FDA-approved label says

The current Prometrium label lists two indications:

• prevention of endometrial hyperplasia in nonhysterectomized postmenopausal patients taking conjugated estrogen tablets; and
• treatment of secondary amenorrhea.

For endometrial-hyperplasia prevention, the labeled regimen is 200 mg by mouth at bedtime for 12 consecutive days in each 28-day cycle. For secondary amenorrhea, the labeled regimen is 400 mg at bedtime for 10 days. These are indication-specific instructions, not a universal menopause regimen.

A continuous regimen such as 100 mg nightly appears in some professional guidance and clinical practice but is not the specific cyclic Prometrium regimen in the current U.S. label. Estrogen dose and route, treatment goal, bleeding pattern, and individual risks can affect the plan. Do not convert between cyclic and continuous schedules without the prescriber.

The label directs bedtime dosing because transient dizziness and drowsiness can occur. Food increases Prometrium exposure, but the label does not tell every patient to take it with a high-fat meal. Follow the instructions for the exact product and use it consistently as directed.

What an evaluation may include

Florida does not require a fixed laboratory bundle before oral progesterone. The FDA label also does not require every patient to obtain progesterone, estradiol, FSH, CBC, metabolic panel, lipids, and liver enzymes before treatment or on a fixed schedule.

The clinician may need to address:

• unexplained vaginal bleeding;
• pregnancy possibility or the reason for secondary amenorrhea;
• current estrogen exposure and whether the patient has a uterus;
• breast cancer or other hormone-sensitive cancer history;
• prior deep-vein thrombosis, pulmonary embolism, stroke, or myocardial infarction;
• known liver dysfunction or disease;
• peanut or other ingredient allergy;
• migraine, seizure, heart, kidney, thyroid, or metabolic conditions; and
• other medicines and supplements.

Tests should answer a clinical question. Pregnancy testing or amenorrhea evaluation may be important for one patient; liver testing may be appropriate when history or symptoms raise concern. Routine serum progesterone targets are not part of the FDA-labeled monitoring instructions for menopausal endometrial protection.

Unexpected or persistent vaginal bleeding requires clinical evaluation rather than only a hormone panel.

Florida telehealth rules

Florida Statute 456.47 requires a telehealth provider to practice within scope and consistently with the prevailing professional standard for in-person care. A provider may evaluate a patient by telehealth; if that evaluation is sufficient to diagnose and treat, the statute does not impose an automatic prior in-person examination [1].

The old claim that every telehealth prescriber must hold a full Florida license is incomplete. Current Florida licensees may provide telehealth without a separate registration, and qualifying out-of-state practitioners may treat Florida patients after registering with the Florida Department of Health [2].

Progesterone is not a controlled substance, so the statute's special restriction on prescribing certain Schedule II controlled substances by telehealth is not the relevant barrier. The real questions are whether the provider is properly authorized, whether the evaluation is clinically sufficient, and whether prescribing is within that provider's scope.

Patients can verify Florida licenses and out-of-state telehealth registrations through the Florida MQA license-verification portal.

Florida Medicaid coverage as of July 2026

Florida Medicaid's Preferred Drug List effective July 1, 2026 lists [11]:

• progesterone 100 mg capsule, generic name progesterone micronized, PA required: No; and
• progesterone 200 mg capsule, generic name progesterone micronized, PA required: No.

This directly contradicts the claim that Florida Medicaid excludes progesterone for hormone therapy or covers it only for type 2 diabetes. Progesterone is not a diabetes treatment.

The PDL warns that a listed product name does not make every NDC reimbursable. Quantity, refill, eligibility, pharmacy network, and other claim edits can still matter. Ask the pharmacy for the exact rejection message if a claim does not pay before assuming a clinical prior authorization is required.

Commercial and Medicare coverage varies by plan, product, quantity, pharmacy, and year. No reliable statewide copay, preferred tier, denial rate, or cash price applies to every Florida patient.

Brand, generic, and peanut oil

The current Prometrium label lists peanut oil in both the 100 mg and 200 mg capsules and contraindicates the product in patients with peanut allergy [3].

Do not assume that a generic is peanut-free. The current Hikma progesterone capsule label, for example, also lists peanut oil [4]. Manufacturers and pharmacy suppliers can change.

For an allergy-sensitive fill:

1. Ask which manufacturer and NDC the pharmacy will dispense.
2. Check that exact product's current label.
3. Have the pharmacist confirm the inactive ingredients.
4. Do not take the capsule while the ingredients remain uncertain.

When compounding may be considered

Compounded progesterone is not FDA-approved, and FDA does not review a compounded drug for safety, effectiveness, or quality before marketing. FDA says compounded drugs should be used only when an approved drug cannot meet a patient's medical need [5]. A clinically significant ingredient allergy or a needed dosage form unavailable as an approved product may be a patient-specific reason.

The prior claim that a 503A pharmacy can never ship across state lines is false. An out-of-state pharmacy shipping a dispensed drug into Florida generally must hold a Florida nonresident-pharmacy registration under section 465.0156 [6]. Separate federal compounding rules and additional Florida permits can apply, particularly to sterile products.

Before using a mail-order or compounding pharmacy, verify its Florida permit in the MQA portal. Ask for the exact ingredients, beyond-use date, storage instructions, and the documented reason an approved product does not meet the patient's need.

What the evidence supports

The PEPI randomized trial found far less endometrial hyperplasia with cyclic progesterone plus conjugated estrogens than with conjugated estrogens alone. This supports adequate endometrial protection for a postmenopausal patient with a uterus using systemic estrogen; it does not make one regimen appropriate for every patient [7].

The 2022 North American Menopause Society position statement emphasizes individualized hormone-therapy decisions. It does not say that micronized progesterone is risk-free or uniformly superior to every synthetic progestin [8].

An observational E3N cohort reported different breast-cancer associations among hormone-therapy formulations, but observational data cannot prove that estrogen plus micronized progesterone eliminates breast-cancer risk [9].

A systematic review of randomized trials found improvement in some sleep outcomes with micronized progesterone, particularly sleep-onset latency, while other results were inconsistent. Drowsiness is also a labeled adverse effect; progesterone should not be promoted as a guaranteed insomnia treatment [10].

Prescription transfer and pharmacy checks

A receiving pharmacy can determine whether an existing noncontrolled prescription is valid and transferable and whether refills remain. If a new prescription is needed while the patient is in Florida, the prescriber must be authorized to treat Florida patients.

An out-of-state pharmacy may ship into Florida if it has the required nonresident registration; 503B status is not the general prerequisite for all interstate prescription dispensing. Verify the actual pharmacy permit instead of relying on the words “503A” or “503B” alone.

Practical checklist

• Confirm the indication and whether the regimen is FDA-labeled or off-label.
• Tell the clinician about unexplained bleeding, pregnancy possibility, cancer, clots, cardiovascular disease, liver disease, allergies, and all medicines.
• Confirm uterus status and any systemic estrogen use.
• Ask why each test is needed; there is no universal Florida hormone-lab bundle.
• Check the exact manufacturer, NDC, and inactive ingredients.
• For Florida Medicaid, use the July 2026 PDL and the pharmacy's live claim response.
• Use a compounded formulation only for a documented patient-specific need.
• Take the medicine exactly as prescribed and follow bedtime/driving precautions.